Cystic Fibrosis Market By Worldwide Analysis, Estimation, Industry Applications, Key Growths 2018 To 2026
Cystic fibrosis (CF)
is a genetic disorder that usually affects the lungs and may also
affect the pancreas, kidneys, liver, and intestine. Long-term
repercussions including difficulty in breathing and coughing as a
result of recurrent lung infections can be seen in CF. Some of the
other signs and symptoms include sinus infections, poor growth,
infertility in males, fatty stool, and guild of the fingers and toes.
Different individuals may have diverse degrees of symptoms. CF is
chiefly inherited as an autosomal recessive gene. It is triggered by
mutations in both the copies of the gene for CFTR or cystic fibrosis
transmembrane conductance regulator protein. Individuals with a
single copy are carriers. Cystic fibrosis transmembrane conductance
regulator protein is involved in the production of digestive fluids,
mucus, and sweat. When the protein is not functional, secretions
otherwise thin become thick. The ailment is mostly diagnosed by
genetic testing and sweat test.
Download the PDF
brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/236
Over the last few
years, advancements in technology have resulted in a shift in
research and development towards treatments that target the
fundamental cause of the disease by targeting the CFTR function.
Moreover, there is an affinity towards licensing the products, and
for that reason alliances are being made by a number of biotechnology
and pharmaceutical manufacturers, since the majority of the
treatments for cystic fibrosis are developed by smaller
manufacturers. The increase in licensing activity along with the rise
in the number of new partnerships will encourage the smaller
companies to continue their research work thereby giving a positive
momentum to the cystic fibrosis market.
In spite of
significant advancement in cystic fibrosis therapeutics, individuals
suffering from CF face significant unmet needs owing to the
deficiency of restorative therapies, inadequate choice of mucolytic
treatments, and the unvarying fight alongside severe lung infection
that needs the expansion of novel antibiotics. These factors are
likely to drive the growth of the cystic fibrosis market during the
forecast period.
Cystic fibrosis
market Taxonomy
On the basis of
therapy type, the global market is classified into:
Cystic Fibrosis
Transmembrane Conductance Regulator (CFTR) Modulators
Protein
Transcription Modulators
Pancreatic Enzyme
Products (PEP)
Other therapies
There are many types
of antibiotics for CF lung infections such as P. aeruginosa and S.
aureus. Nevertheless, excessive use of the drug may lead to resistant
strains of the gene. Antibiotics are the most common treatment regime
in CF, since they are mainly used to eliminate pathogens in recently
infected patients. Antibiotics are used on a long-term basis to avoid
the requirement of more serious hospital treatments as a result of
their ability to control the infection. The requirement for a more
wide range of antibiotics is mirrored in the CF treatment market,
with more than a few novel antibiotics in active development phase.
This dynamic nature of the treatment for CF will encourage the growth
of the global CF market.
High prevalence of
genetic diseases including CF will drive the overall cystic fibrosis
market
According to
Netwellness, a community service provider, 3 to 4% of the babies are
born with genetic disorders. This number is poised to rise in the
coming years, especially in the emerging economies of Asia pacific
such as China and India owing to high birth rate observed in these
regions. As the number of cases of CF rises, so will the demand for
CF treatment, thereby augmenting the growth of the overall cystic
fibrosis market during the forecast period.
On the basis of
geography North America held the maximum market share in the
cystic fibrosis market globally. Constructive and favorable
regulations and policies as well as high availability of
sophisticated healthcare facilities and rising approvals of drugs for
treating CF are likely to propel the growth of the cystic fibrosis
industry in this region.
Some of the key
players operating in the global cystic fibrosis market are
AbbVie, Inc., Aradigm, Aurora Biosciences, Bayer AG, Demegen, EryDel,
Genentech, Inc., InDex Pharmaceuticals,
Click To
Read More On Cystic
Fibrosis Market
Comments
Post a Comment